Skip to main content
SpringerLink
Log in
Book cover

Arzneiverordnungs-Report 2012 pp 803–817Cite as

Osteoporosemittel

  • Chapter

Zusammenfassung

Grundlage der Behandlung der Osteoporose sind (neben Schmerzmitteln) nichtmedikamentöse Maßnahmen und eine ausreichende Zufuhr von Calcium und Vitamin D als Basistherapie (Rizzoli et al. 2008). Die spezifische Osteoporosetherapie stützt sich auf den Einsatz der knochenabbauhemmenden Antiresorptiva (Bisphosphonate, Raloxifen, Denosumab) und der knochenaufbaufördernden Osteoanabolika (Strontiumranelat, Teriparatid, Parathormon) (Übersicht bei Rachner et al. 2011).

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   59.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • American Medical Association (1986): Agents affecting calcium metabolism. In: Drug Evaluations, 6th ed, Saunders Company, Philadelphia, pp. 827-839, 885-902.

    Google Scholar 

  • Arzneimittelkommission der Deutschen Ärzteschaft (2008): Empfehlungen zur Therapie und Prophylaxe der Osteoporose. Arzneiverordnung in der Praxis (Sonderheft 34S), 2. Auflage. Im Internet: www.akdae.de/35/83_0steoporose_2008_2Auflage.pdf

  • Bilezikian JP, Matsumoto T, Bellido T, Khosla S, Martin J, Recker RR, Heaney R, Seeman E, Papapoulos S, Goldring SR (2009): Targeting bone remodeling for the treatment of osteoporosis: summary of the proceedings of an ASBMR Workshop. J Bone Miner Res 24: 373-385.

    Google Scholar 

  • Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG (2004): Cinacalcet for secondary hyperparathyroidism in patients receiving he- modialysis. N Engl J Med 350: 1516-1525.

    Article  PubMed  CAS  Google Scholar 

  • Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM (2007): Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 71: 438-441.

    Article  PubMed  CAS  Google Scholar 

  • Bolland MJ, Avenell A, Baron JA, Grey A, MacLennan GS, Gamble GD, Reid IR (2010): Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 341: c3691.

    Article  Google Scholar 

  • Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, Rodriguez- Portales JA, Downs RW, Gupta J, Santora AC, Liberman UA; Alendronate Phase III Osteoporosis Treatment Study Group (2004): Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189-1199.

    Article  PubMed  CAS  Google Scholar 

  • Brancaccio D, Cozzolino M (2007): Lanthanum carbonate: time to abandon prejudices? Kidney Int 71: 190-192.

    Article  PubMed  CAS  Google Scholar 

  • Brown JE, Coleman RE (2012): Denosumab in patients with cancer-a surgical strike 37 against the osteoclast. Nat Rev Clin Oncol 9: 110-118.

    Article  PubMed  CAS  Google Scholar 

  • Compston J (2009): Recent advances in the management of osteoporosis. Clin Med 9: 565-569.

    PubMed  Google Scholar 

  • Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C; FREEDOM Trial (2009): Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361: 756-765.

    Article  PubMed  CAS  Google Scholar 

  • Diez-Perez A, Olmos JM, Nogues X, Sosa M, Diaz-Curiel M, Perez-Castrillön JL, Perez- Cano R, Munoz-Torres M, Torrijos A, Jodar E, Del Rio L, Caeiro-Rey JR, Farrerons J, Vila J, Arnaud C, Gonzalez-Macias J (2012): Risk factors for prediction of inadequate response to antiresorptives. J Bone Miner Res 27: 817-824.

    Article  PubMed  CAS  Google Scholar 

  • Drüeke TB (2007): Lanthanum carbonate as a first-line phosphate binder: the „cons". Semin Dial 20: 329-332.

    Article  PubMed  Google Scholar 

  • Eastell R, Nagase S, Ohyama M, Small M, Sawyer J, Boonen S, Spector T, Kuwayama T, Deacon S (2011): Safety and efficacy of the cathepsin K inhibitor ONO-5334 in post- menopausal osteoporosis: the OCEAN study. J Bone Miner Res 26: 1303-1312.

    Article  PubMed  CAS  Google Scholar 

  • Ensrud KE, Stock JL, Barrett-Connor E, Grady D, Mosca L, Khaw KT, Zhao Q, Agnusdei D, Cauley JA (2008): Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial. J Bone Miner Res 23: 112-120.

    Article  PubMed  CAS  Google Scholar 

  • Favia G, Pilolli GP, Maiorano E (2009): Histologic and histomorphometric features of bisphosphonate-related osteonecrosis of the jaws: an analysis of 31 cases with confocal laser scanning microscopy. Bone 45: 406-413.

    Article  PubMed  CAS  Google Scholar 

  • Hersh AL, Stefanick ML, Stafford RS (2004): National use of postmenopausal hormone therapy. Annual trends and response to recent evidence. JAMA 291: 47-53.

    Article  PubMed  CAS  Google Scholar 

  • Jackson RD, LaCroix AZ, Gass M, Wallace RB, Robbins J, Lewis CE et al.; Women's Health Initiative Investigators (2006): Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 354: 669-683.

    Article  PubMed  CAS  Google Scholar 

  • Keaveny TM, Donley DW, Hoffmann PF et al. (2007): Effects of teriporatide and alend- ronate on vertebral strength as assessed by finite element modeling of QCT scars in women with osteoporosis. J Bone Miner Res 21: 149-157.

    Google Scholar 

  • Lyles KW, Colon-Emeric CS, Magaziner JS, Adachi JP, Pieger CF, Mautalen C, Hyldstrup L, Recknor C, Nordsletten L, Moore KA, Lavecchia C, Zhang J, Mesenbrink P, Hodgson PK, Abrams K, Orloff JJ, Horowitz Z, Eriksen EF, Boonen S; HORIZON Recurrent Fracture Trial (2007): Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357: 1799-1810.

    Article  PubMed  CAS  Google Scholar 

  • Manns B, Klarenbach S, Lee H, Culleton B, Shrive F, Tonelli M (2007): Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 22: 2867-2878.

    Article  PubMed  Google Scholar 

  • Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY (2004): The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350: 459-486.

    Article  PubMed  CAS  Google Scholar 

  • Mousny M, Bouse X, Wise L, Everett ET, Hancock R, Vieth R, Devogelaer JP, Grynpas MD (2006): The genetic influence on bone susceptibility to fluoride. Bone 39: 1283-1289.

    Article  PubMed  CAS  Google Scholar 

  • NIH Consensus Conference (1994): Optimal calcium intake. JAMA 272: 1942-1948.

    Article  Google Scholar 

  • Pazianas M, Compston J, Huang CL (2010): Atrial fibrillation and bisphosphonate thera- py. J Bone Miner Res 25: 2-10.

    Article  PubMed  CAS  Google Scholar 

  • Rachner TD, Khosla S, Hofbauer LC (2011): Osteoporosis: now and the future. Lancet 377: 1276-1287.

    Article  PubMed  CAS  Google Scholar 

  • Reginster JY, Bruyere O, Sawicki A, Roces-Varela A, Fardellone P, Roberts A, Devogelaer JP (2009): Long-term treatment of postmenopausal osteoporosis with strontium ra- nelate: results at 8 years. Bone 45: 1059-1064.

    Article  PubMed  CAS  Google Scholar 

  • Rizzoli R, Boonen S, Brandi ML, Burlet N, Delmas P, Reginster JY (2008): The role of calcium and vitamin D in the management of osteoporosis. Bone 42: 246-249.

    Article  PubMed  CAS  Google Scholar 

  • Sainz M, del Pozo JG, Arias LH, Carvajal A (2009): Strontium ranelate may cause alopecia. BMJ 338: 1494-1498.

    Article  Google Scholar 

  • Schousboe JT, Nyman JA, Kane RL, Eusrud KE (2005): Cost-effectiveness of alendronate therapy for osteopenic postmenopausal women. Ann Intern Med 142: 734-741.

    PubMed  Google Scholar 

  • Seeman E, Devogelaer J-P, Lorenc R, Spector T, Brixeu K, Balogh A, Stucki G, Reginster JY (2008): Strontium ranelate reduces the risk of vertebral fractures in patients with osteopenia. J Bone Miner Res 23: 433-438.

    Article  PubMed  CAS  Google Scholar 

  • Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M; American Society for Bone and Mineral Research (2010): Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25: 2267-2294.

    Article  PubMed  Google Scholar 

  • Silverberg SJ, Fairman C, Bilezikian JP et al. (2004): Cinacalcet HCl effectively treats hypercalcemia in patients with parathyroid carcinoma (abstract no. SA495). J Bone Miner Res 19 Suppl. 1: S103.

    Google Scholar 

  • Suki W, Zabaneh R, CangianoJ, Reed J, Fischer D, Garrett L, Ling B, Chasan-Taber S, Dillon M, Blair A, Burke S (2006): A prospective, randomized trial assessing the im- pact on outcomes of sevelamer in dialysis patients. The DCOR trial. Nephrol Dial Transplant 21 (Suppl 4): 145-146.

    Google Scholar 

  • Tashjian AH Jr, Goltzman D (2008): On the interpretation of rat carcinogenicity studies for human PTH(1-34) and human PTH(1-84). J Bone Miner Res 23: 803-811.

    Article  PubMed  CAS  Google Scholar 

  • Wade SW, Curtis JR, Yu J, White J, Stolshek BS, Merinar C, Balasubramanian A, Kallich JD, Adams JL, Viswanathan HN (2012): Medication adherence and fracture risk among patients on bisphosphonate therapy in a large United States health plan. Bone 50: 870-875.

    Article  PubMed  Google Scholar 

  • Ziegler R (2002): Osteoporose: aktuelle Diagnostik und Therapie. Orthopädische Praxis 38: 570-577.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmakologisches Institut, Universität Heidelberg, Neuenheimer Feld 366, 69120, Heidelberg

    Prof. Dr. med. Ulrich Schwabe

  2. Mozartstraße 20, 69121, Heidelberg

    Prof. Dr. med. h.c. Reinhard Ziegler

Authors
  1. Prof. Dr. med. Ulrich Schwabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. h.c. Reinhard Ziegler
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Medizin Verlag Berlin, Heidelberg

About this chapter

Cite this chapter

Schwabe, U., Ziegler, R. (2012). Osteoporosemittel. In: Arzneiverordnungs-Report 2012. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-29242-2_37

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-29242-2_37

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-29241-5

  • Online ISBN: 978-3-642-29242-2

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation